GlaxoSmithKline PLC
LSE:GSK
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.2B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
239B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
GlaxoSmithKline PLC
Glance View
Once upon a time, in the bustling world of pharmaceuticals, GlaxoSmithKline PLC established itself as a formidable player. Born out of mergers and continuous evolution, GSK, as it is commonly known, carved its place in the competitive landscape through strategic research and pioneering innovations. The company operates at the intersection of pharmaceuticals, vaccines, and consumer healthcare, leveraging its breadth to tackle some of the world's most pressing health challenges. From its bustling laboratories to clinical trials, and finally to market, GSK is driven by a mission to improve the quality of human life. Its intricate network of research facilities and production plants stretch across the globe, working tirelessly to develop essential medications and vaccines that span a variety of therapeutic areas including respiratory, HIV, oncology, and immunology. GSK’s revenue streams flow from a well-diversified portfolio. The pharmaceutical division, representing the lion’s share, innovates and produces transformative medicines. Its vaccines division stands strong, leading with essential inoculations that prevent childhood and adult diseases, while the consumer healthcare segment provides everyday wellness products ranging from pain relief to vitamins and skincare. This triad not only underscores GSK’s dynamic adaptability to market needs but also highlights its resilience in weathering the cyclical nature of the healthcare industry. With a keen eye on long-term value and sustained investment in research and development, GSK continues to create a bridge between scientific advancements and societal well-being, defining its role as both a scientific leader and a profit-driven enterprise.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for GlaxoSmithKline PLC is 27.5%, which is above its 3-year median of 26.1%.
Over the last 3 years, GlaxoSmithKline PLC’s Operating Margin has decreased from 28.6% to 27.5%. During this period, it reached a low of 25% on Mar 31, 2025 and a high of 28.6% on Dec 31, 2022.